0     

Earla JR, Li J, Hutton GJ, Johnson ML, Aparasu RR. Comparative adherence trajectories of oral disease-modifying agents in multiple sclerosis. Pharmacotherapy. 2023;43(6):473-84. PMID: 37157135.

0     

Li J, Huang Y, Hutton GJ, Aparasu RR. Assessing treatment switch among patients with multiple sclerosis: A machine learning approach. Explor Res Clin Soc Pharm. 2023;11:100307. PMID: 37554927.

0     

Moore MZ, Perez CA, Hutton GJ, Patel H, Cuascut FX. Health disparities in multiple sclerosis among Hispanic and Black populations in the United States. Biomedicines. 2023;11(4):. PMID: 37189845.

0     

Pérez CA, Cuascut FX, Hutton GJ. Immunopathogenesis, diagnosis, and treatment of multiple sclerosis: A clinical update. Neurol Clin. 2023;41(1):87-106. PMID: 36400561.

0     

Alkabie S, Tanweer O, Hutton GJ, Cuascut FX. Clinical reasoning: A 57-year-old man with stepwise progressive paraparesis, sensory loss, urinary retention, and constipation. Neurology. 2022;98(5):e555-60. PMID: 34799458.

0     

Choudhury NA, Castrodad-Molina RM, Hutton GJ, Cuascut FX. Elsberg syndrome following acute immunosuppressive treatment for multiple sclerosis relapse. Mult Scler Relat Disord. 2022;58:103498. PMID: 35007821.

0     

Li J, Chikermane SG, Earla JR, Hutton GJ, Aparasu RR. Factors associated with switching from injectable to oral disease modifying agents among patients with multiple sclerosis. Mult Scler Relat Disord. 2022;60:103703. PMID: 35278846.

0     

Li J, Zakeri M, Hutton GJ, Aparasu RR. Health-related quality of life of patients with multiple sclerosis: Analysis of ten years of national data. Mult Scler Relat Disord. 2022;66:104019. PMID: 35839614.

0     

Talwar A, Earla JR, Hutton GJ, Aparasu RR. Prescribing of disease modifying agents in older adults with multiple sclerosis. Mult Scler Relat Disord. 2022;57:103308. PMID: 35158421.

0     

Alkabie S, Castrodad-Molina R, Heck KA, Mandel J, Hutton GJ. The concurrence of multiple sclerosis and glioblastoma. Mult Scler Relat Disord. 2021;50:102877. PMID: 33711579.

0     

Cuascut FX, Alkabie S, Hutton GJ. Fingolimod-related cryptococcal meningoencephalitis and immune reconstitution inflammatory syndrome in a patient with multiple sclerosis. Mult Scler Relat Disord. 2021;53:103072. PMID: 34139459.

0     

Earla JR, Hutton GJ, Thornton DJ, Chen H, Johnson ML, Aparasu RR. Comparative treatment effectiveness of oral fingolimod and conventional injectable disease-modifying agents in multiple sclerosis. Pharmacotherapy. 2021;41(5):440-50. PMID: 33641232.

0     

Lee H, Nakamura K, Narayanan S, Brown RA, Nash RA, Griffith LM, et al. Brain volume change after high-dose immunosuppression and autologous hematopoietic cell transplantation for relapsing-remitting multiple sclerosis. Mult Scler Relat Disord. 2021;54:103149. PMID: 34284316.

0     

Earla JR, Hutton GJ, Thornton JD, Aparasu RR. Factors associated with prescribing oral disease modifying agents in multiple sclerosis: A real-world analysis of electronic medical records. Mult Scler Relat Disord. 2020;45:102334. PMID: 32629400.

0     

Earla JR, Hutton GJ, Thornton JD, Chen H, Johnson ML, Aparasu RR. Comparative adherence trajectories of oral fingolimod and injectable disease modifying agents in multiple sclerosis. Patient Prefer Adherence. 2020;14:2187-99. PMID: 33177813.

0     

Earla JR, Paranjpe R, Kachru N, Hutton GJ, Aparasu RR. Use of disease modifying agents in patients with multiple sclerosis: Analysis of ten years of national data. Res Social Adm Pharm. 2020;16(12):1670-6. PMID: 32171597.

0     

Earla JR, Thornton JD, Hutton GJ, Aparasu RR. Marginal health care expenditure burden among U.S. civilian noninstitutionalized individuals with multiple sclerosis: 2010-2015. J Manag Care Spec Pharm. 2020;26(6):741-9. PMID: 32463779.

0     

Fisher KS, Cuascut FX, Rivera VM, Hutton GJ. Current advances in pediatric onset multiple sclerosis. Biomedicines. 2020;8(4):. PMID: 32231060.

0     

Mercado V, Dongarwar D, Fisher K, Salihu HM, Hutton GJ, Cuascut FX. Multiple sclerosis in a multi-ethnic population in Houston, Texas: A retrospective analysis. Biomedicines. 2020;8(12):. PMID: 33255552.

0     

Oh J, Achiron A, Celius EG, Chambers C, Derwenskus J, Devonshire V, et al. Pregnancy outcomes and postpartum relapse rates in women with RRMS treated with alemtuzumab in the phase 2 and 3 clinical development program over 16 years. Mult Scler Relat Disord. 2020;43:102146. PMID: 32498033.

0     

Wang KY, Carlton J, Guffey D, Hutton GJ, Moron FE. Histogram analysis of apparent diffusion coefficient and fluid-attenuated inversion recovery in discriminating between enhancing and nonenhancing lesions in multiple sclerosis. Clin Imaging. 2020;59(1):13-20. PMID: 31715512.

7

Cuascut FX, Hutton GJ. Stem cell-based therapies for multiple sclerosis: Current perspectives. Biomedicines. 2019;7(2):. PMID: 30935074.

0     

Yeo CJJ, Hutton GJ, Fung SH. Advanced neuroimaging in Balo's concentric sclerosis: MRI, MRS, DTI, and ASL perfusion imaging over 1 year. Radiol Case Rep. 2018;13(5):1030-5. PMID: 30228838.

43

Nash RA, Hutton GJ, Racke MK, Popat U, Devine SM, Steinmiller KC, et al. High-dose immunosuppressive therapy and autologous HCT for relapsing-remitting MS. Neurology. 2017;88(9):842-52. PMID: 28148635.

2

Mandel JJ, Goethe EA, Patel AJ, Heck K, Hutton GJ. Newly diagnosed ganglioglioma in an adult patient with multiple sclerosis. J Neurol Sci. 2016;369:51-2. PMID: 27653865.

0     

Miller DH, Fox RJ, Phillips JT, Hutchinson M, Havrdova E, Kita M, et al. Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study. Neurology. 2015;84(11):1145-52. PMID: 25681448.

96

Nash RA, Hutton GJ, Racke MK, Popat U, Devine SM, Griffith LM, et al. High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for relapsing-remitting multiple sclerosis (HALT-MS): a 3-year interim report. JAMA Neurol. 2015;72(2):159-69. PMID: 25546364.

9

Yapundich R, Applebee A, Bethoux F, Goldman MD, Hutton GJ, Mass M, et al. Evaluation of dalfampridine extended release 5 and 10 mg in multiple sclerosis: A randomized controlled trial. Int J MS Care. 2015;17(3):138-45. PMID: 26052259.

0     

Hutton J, Hutton GJ. Congenital rubella with autism and evidence of a remote stroke. J Vaccines Vaccin. 2014;5:258. DOI: 10.4172/2157-7560.1000258.

3

Schurmann P, Basra S, Awar OG, Aguilar D, Basant A, Dragan E, et al. Abnormal rhythms in patients without known cardiac disease after a first dose of fingolimod. Mult Scler Relat Disord. 2014;3(3):408-12. PMID: 25876482.

0     

Lublin FD, Cofield SS, Cutter GR, Conwit R, Narayana PA, Nelson F, et al. Randomized study combining interferon and glatiramer acetate in multiple sclerosis. Ann Neurol. 2013;73(3):327-40. PMID: 23424159.

43

Chen M, Chen G, Deng S, Liu X, Hutton GJ, Hong J. IFN-beta induces the proliferation of CD4+CD25+Foxp3+ regulatory T cells through upregulation of GITRL on dendritic cells in the treatment of multiple sclerosis. J Neuroimmunol. 2012;242(1-2):39-46. PMID: 22112394.

0     

Cohen JA, Coles AJ, Arnold DL, Confavreux C, Fox EJ, Hartung HP, et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: A randomised controlled phase 3 trial. Lancet. 2012;380(9856):1819-28. PMID: 23122652.

0     

Coles AJ, Twyman CL, Arnold DL, Cohen JA, Confavreux C, Fox EJ, et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet. 2012;380(9856):1829-39. PMID: 23122650.

0     

Fox RJ, Miller DH, Phillips JT, Hutchinson M, Havrdova E, Kita M, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med. 2012;367(12):1087-97. PMID: 22992072.

0     

Saccardi R, Freedman MS, Sormani MP, Atkins H, Farge D, Griffith LM, et al. A prospective, randomized, controlled trial of autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: a position paper. Mult Scler. 2012;18(6):825-34. PMID: 22383228.

0     

Avila-Ornelas J, Avila M, Stosic M, Robles L, Prieto PG, Hutton GJ, et al. The role of postpartum intravenous corticosteroids in the prevention of relapses in multiple sclerosis. Int J MS Care. 2011;13(2):91-3. PMID: 24453710.

11

Stosic M, De Jesus P, McCarthy J, Hutton G, Rivera V. Immune thrombocytopenic purpura in a patient with multiple sclerosis treated with natalizumab. Neurology. 2011;77(5):505-7. PMID: 21775738.

0     

Cohen JA, Barkhof F, Comi G, Hartung HP, Khatri BO, Montalban X, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med. 2010;362(5):402-15. PMID: 20089954.

26

Helekar SA, Shin JC, Mattson BJ, Bartley K, Stosic M, Saldana-King T, et al. Functional brain network changes associated with maintenance of cognitive function in multiple sclerosis. Front Hum Neurosci. 2010;4:219. PMID: 21152340.

8

Hong J, Hutton GJ. Regulatory effects of interferon-beta on osteopontin and interleukin-17 expression in multiple sclerosis. J Interferon Cytokine Res. 2010;30(10):751-7. PMID: 20874252.

0     

Hutton GJ. Vitamin D and MS: implications for patient care. Pract Neurol. 2010;9:22-4.

72

Cohen JA, Imrey PB, Calabresi PA, Edwards KR, Eickenhorst T, Felton WL, et al. Results of the Avonex Combination Trial (ACT) in relapsing-remitting MS. Neurology. 2009;72(6):535-41. PMID: 19204263.

0     

Hawker K, O'Connor P, Freedman MS, Calabresi PA, Antel J, Simon J, et al. Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol. 2009;66(4):460-71. PMID: 19847908.

3

Hutton GJ, Avila M, Suarez GA. Pneumocephalus after an epidural steroid injection. Clin Neurol Neurosurg. 2009;111(3):309-10. PMID: 19036497.

0     

Pachner AR, Warth JD, Pace A, Goelz S, INSIGHT Investigators. Effect of neutralizing antibodies on biomarker responses to interferon beta: The INSIGHT study. Neurology. 2009;73(18):1493-500. PMID: 19884577.

698

CAMMS Trial Investigators , Coles AJ, Compston DA, Selmaj KW, Lake SL, Moran S, et al. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med. 2008;359(17):1786-801. PMID: 18946064.

17

Cohen JA, Calabresi PA, Chakraborty S, Edwards KR, Eickenhorst T, Felton WL, et al. Avonex Combination Trial in relapsing--remitting MS: Rationale, design and baseline data. Mult Scler. 2008;14(3):370-82. PMID: 18208877.

132

Lotze TE, Northrop JL, Hutton GJ, Ross B, Schiffman JS, Hunter JV. Spectrum of pediatric neuromyelitis optica. Pediatrics. 2008;122(5):e1039-47. PMID: 18838462.

6

Nash RA, Stuve O, Bowen JD, Frohman EM, Griffith LM, Hutton GJ, et al. Autologous HSCT for advanced MS: Is the glass half-empty or really half-full? Brain. 2008;131(Pt 2):e89; author reply e90. PMID: 17908695.

343

Optic Neuritis Study Group. Multiple sclerosis risk after optic neuritis: Final optic neuritis treatment trial follow-up. Arch Neurol. 2008;65(6):727-32. PMID: 18541792.

99

Optic Neuritis Study Group. Visual function 15 years after optic neuritis: a final follow-up report from the Optic Neuritis Treatment Trial. Ophthalmology. 2008;115(6):1079-82 e5. PMID: 17976727.

1

Suarez Zambrano GA, Hutton GJ. Heart-shaped lesion secondary to neurosarcoidosis. Arch Neurol. 2008;65(10):1388-9. PMID: 18852359.

0     

Suarez GA, Hutton GJ, Rivera VM. Optic neuritis: Relation with multiple sclerosis. Acta Neurol Colomb. 2007;23:141-6.

0     

Suarez GA, Lotze TE, Hutton GJ, Rivera VM. Multiple sclerosis in the pediatric population. Acta Neurol Colomb. 2007;23:134-40.

64

Vu T, Carrum G, Hutton G, Heslop HE, Brenner MK, Kamble R. Human herpesvirus-6 encephalitis following allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2007;39(11):705-9. PMID: 17401392.

0     

Hutton G, Miller JR, Radue EW. MR finds widespread clinical use in MS diagnosis, management. Diagn Imaging. 2005;27:36-45.

0     

Hutton G, Miller JR, Radue EW. Multiple sclerosis: MRI in diagnosis, management, and monitoring. Appl Neurol. 2005;6(26-35):.

0     

Hutton G. Does "benign multiple sclerosis" really exist? Pract Neurol. 2005;4(3):27-9.

14

Zhang J, Hutton G. Role of magnetic resonance imaging and immunotherapy in treating multiple sclerosis. Annu Rev Med. 2005;56:273-302. PMID: 15660513.

33

Bakshi R, Hutton GJ, Miller JR, Radue EW. The use of magnetic resonance imaging in the diagnosis and long-term management of multiple sclerosis. Neurology. 2004;63(11 Suppl 5):S3-11. PMID: 15596734.

0     

Beck RW, Gal RL, Bhatti MT, Brodsky MC, Buckley EG, Chrousos GA, et al. Visual function more than 10 years after optic neuritis: experience of the optic neuritis treatment trial. Am J Ophthalmol. 2004;137(1):77-83. PMID: 14700647.

0     

Beck RW, Smith CH, Gal RL, Xing D, Bhatti MT, Brodsky MC, et al. Neurologic impairment 10 years after optic neuritis. Arch Neurol. 2004;61(9):1386-9. PMID: 15364684.

58

Hong J, Zang YC, Hutton G, Rivera VM, Zhang JZ. Gene expression profiling of relevant biomarkers for treatment evaluation in multiple sclerosis. J Neuroimmunol. 2004;152(1-2):126-39. PMID: 15223245.

0     

Optic Neuritis Study Group. Long-term brain magnetic resonance imaging changes after optic neuritis in patients without clinically definite multiple sclerosis. Arch Neurol. 2004;61(10):1538-41. PMID: 15477507.

0     

Rivera-Olmos VM, Hutton GJ, Breitbach WT. Discrepancia entre clinica e imagen: Esclerosis multiple en fase intermedia. Presentacion de un caso y revision del tema [Discrepancy between clinics and image techniques: Intermediate phase of multiple sclerosis. A case report and review of the literature]. Rev Mex Neuroci. 2004;5(2):158-62.

73

Sun W, Popat U, Hutton G, Zang YC, Krance R, Carrum G, et al. Characteristics of T-cell receptor repertoire and myelin-reactive T cells reconstituted from autologous haematopoietic stem-cell grafts in multiple sclerosis. Brain. 2004;127(Pt 5):996-1008. PMID: 14985264.

22

Zang YC, Skinner SM, Robinson RR, Li S, Rivera VM, Hutton GJ, et al. Regulation of differentiation and functional properties of monocytes and monocyte-derived dendritic cells by interferon beta in multiple sclerosis. Mult Scler. 2004;10(5):499-506. PMID: 15471364.

0     

Beck RW, Trobe JD, Moke PS, Gal RL, Xing D, Bhatti MT, et al. High- and low-risk profiles for the development of multiple sclerosis within 10 years after optic neuritis: Experience of the optic neuritis treatment trial. Arch Ophthalmol. 2003;121(7):944-9. PMID: 12860795.

35

Zhang J, Hutton G, Zang Y. A comparison of the mechanisms of action of interferon beta and glatiramer acetate in the treatment of multiple sclerosis. Clin Ther. 2002;24(12):1998-2021. PMID: 12581542.